Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma

Danielle S. Wallace; Chris Rowland; Brian T. Hill; Andrea M. Baran; Carla Casulo; Patrick M. Reagan; Allison Winter; Reem Karmali; Jane N. Winter; Leo I. Gordon; Andrew Bui; Peter Sportelli; Hari P. Miskin; Michael S. Weiss; Jonathan W. Friedberg; Shuo Ma; Paul M. Barr

doi:10.1080/10428194.2023.2223743

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma

Danielle S. Wallace^*, Chris Rowland, Brian T. Hill, Andrea M. Baran, Carla Casulo, Patrick M. Reagan, Allison Winter, Reem Karmali, Jane N. Winter, Leo I. Gordon, Andrew Bui, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jonathan W. Friedberg, Shuo Ma, Paul M. Barr

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1579-1582
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	64
Issue number	9
DOIs	https://doi.org/10.1080/10428194.2023.2223743
State	Published - 2023

Funding

for this trial was provided by TG Therapeutics. DSW and PMB analyzed the data and wrote the paper. CR and AB analyzed the data, provided statistical support, and contributed to the paper. BTH, CC, PMR, AW, RK, JNW, LEO, AB, PS, HPM, MSW, JWF, SH, and PMB conducted the research, reviewed, and contributed to the paper. PMR: research funding from Roche/Genentech, consulting for Kite Pharma/Gilead and Caribou Biosciences

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2023.2223743

Cite this

Wallace, D. S., Rowland, C., Hill, B. T., Baran, A. M., Casulo, C., Reagan, P. M., Winter, A., Karmali, R., Winter, J. N., Gordon, L. I., Bui, A., Sportelli, P., Miskin, H. P., Weiss, M. S., Friedberg, J. W., Ma, S., & Barr, P. M. (2023). Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma. Leukemia and Lymphoma, 64(9), 1579-1582. https://doi.org/10.1080/10428194.2023.2223743

@article{bd924cfb967d4b0e8db890cd2ce1911e,

title = "Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma",

author = "Wallace, {Danielle S.} and Chris Rowland and Hill, {Brian T.} and Baran, {Andrea M.} and Carla Casulo and Reagan, {Patrick M.} and Allison Winter and Reem Karmali and Winter, {Jane N.} and Gordon, {Leo I.} and Andrew Bui and Peter Sportelli and Miskin, {Hari P.} and Weiss, {Michael S.} and Friedberg, {Jonathan W.} and Shuo Ma and Barr, {Paul M.}",

note = "Funding Information: for this trial was provided by TG Therapeutics. DSW and PMB analyzed the data and wrote the paper. CR and AB analyzed the data, provided statistical support, and contributed to the paper. BTH, CC, PMR, AW, RK, JNW, LEO, AB, PS, HPM, MSW, JWF, SH, and PMB conducted the research, reviewed, and contributed to the paper. Funding Information: PMR: research funding from Roche/Genentech, consulting for Kite Pharma/Gilead and Caribou Biosciences ",

year = "2023",

doi = "10.1080/10428194.2023.2223743",

language = "English (US)",

volume = "64",

pages = "1579--1582",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "9",

}

Wallace, DS, Rowland, C, Hill, BT, Baran, AM, Casulo, C, Reagan, PM, Winter, A, Karmali, R , Winter, JN , Gordon, LI, Bui, A, Sportelli, P, Miskin, HP, Weiss, MS, Friedberg, JW, Ma, S & Barr, PM 2023, 'Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma', Leukemia and Lymphoma, vol. 64, no. 9, pp. 1579-1582. https://doi.org/10.1080/10428194.2023.2223743

TY - JOUR

T1 - Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma

AU - Wallace, Danielle S.

AU - Rowland, Chris

AU - Hill, Brian T.

AU - Baran, Andrea M.

AU - Casulo, Carla

AU - Reagan, Patrick M.

AU - Winter, Allison

AU - Karmali, Reem

AU - Winter, Jane N.

AU - Gordon, Leo I.

AU - Bui, Andrew

AU - Sportelli, Peter

AU - Miskin, Hari P.

AU - Weiss, Michael S.

AU - Friedberg, Jonathan W.

AU - Ma, Shuo

AU - Barr, Paul M.

N1 - Funding Information: for this trial was provided by TG Therapeutics. DSW and PMB analyzed the data and wrote the paper. CR and AB analyzed the data, provided statistical support, and contributed to the paper. BTH, CC, PMR, AW, RK, JNW, LEO, AB, PS, HPM, MSW, JWF, SH, and PMB conducted the research, reviewed, and contributed to the paper. Funding Information: PMR: research funding from Roche/Genentech, consulting for Kite Pharma/Gilead and Caribou Biosciences

PY - 2023

Y1 - 2023

UR - http://www.scopus.com/inward/record.url?scp=85164145042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85164145042&partnerID=8YFLogxK

U2 - 10.1080/10428194.2023.2223743

DO - 10.1080/10428194.2023.2223743

M3 - Letter

C2 - 37341984

AN - SCOPUS:85164145042

SN - 1042-8194

VL - 64

SP - 1579

EP - 1582

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 9

ER -

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this